IL151106A0 - Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis - Google Patents

Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis

Info

Publication number
IL151106A0
IL151106A0 IL15110601A IL15110601A IL151106A0 IL 151106 A0 IL151106 A0 IL 151106A0 IL 15110601 A IL15110601 A IL 15110601A IL 15110601 A IL15110601 A IL 15110601A IL 151106 A0 IL151106 A0 IL 151106A0
Authority
IL
Israel
Prior art keywords
histamines
leukotriene
conjunctivitis
influence
action
Prior art date
Application number
IL15110601A
Other languages
English (en)
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Publication of IL151106A0 publication Critical patent/IL151106A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL15110601A 2000-02-17 2001-02-05 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis IL151106A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10007203A DE10007203A1 (de) 2000-02-17 2000-02-17 Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
PCT/EP2001/001190 WO2001060407A2 (de) 2000-02-17 2001-02-05 Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis

Publications (1)

Publication Number Publication Date
IL151106A0 true IL151106A0 (en) 2003-04-10

Family

ID=7631276

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15110601A IL151106A0 (en) 2000-02-17 2001-02-05 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
IL151106A IL151106A (en) 2000-02-17 2002-08-06 A preparation containing azlastin and substances that affect the action of leucotrian for the treatment of rhinitis / otitis media

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151106A IL151106A (en) 2000-02-17 2002-08-06 A preparation containing azlastin and substances that affect the action of leucotrian for the treatment of rhinitis / otitis media

Country Status (27)

Country Link
US (1) US6436924B2 (xx)
EP (1) EP1265615B1 (xx)
JP (1) JP5529362B2 (xx)
KR (1) KR100764329B1 (xx)
CN (1) CN1241569C (xx)
AR (1) AR027528A1 (xx)
AT (1) ATE287266T1 (xx)
AU (1) AU781177B2 (xx)
BR (1) BR0108445A (xx)
CZ (1) CZ296395B6 (xx)
DE (2) DE10007203A1 (xx)
DK (1) DK1265615T3 (xx)
ES (1) ES2236189T3 (xx)
HK (1) HK1053792A1 (xx)
HU (1) HU228927B1 (xx)
IL (2) IL151106A0 (xx)
MX (1) MXPA02008064A (xx)
NO (1) NO328153B1 (xx)
NZ (1) NZ520470A (xx)
PL (1) PL198357B1 (xx)
PT (1) PT1265615E (xx)
RU (1) RU2292208C2 (xx)
SK (1) SK285990B6 (xx)
TW (1) TWI296525B (xx)
UA (1) UA72587C2 (xx)
WO (1) WO2001060407A2 (xx)
ZA (1) ZA200206575B (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
WO2003101434A2 (en) * 2001-12-21 2003-12-11 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
CA2502357A1 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
WO2004069338A1 (en) * 2003-01-31 2004-08-19 Schering Corporation Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
EP1670445A2 (en) * 2003-09-17 2006-06-21 Decode Genetics EHF. Methods of preventing or treating recurrence of myocardial infarction
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
PT1713473E (pt) * 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
AU2005210084B2 (en) * 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
DK2522365T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
PL1863476T3 (pl) * 2005-03-16 2016-07-29 Meda Pharma Gmbh & Co Kg Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2007071313A2 (en) * 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
WO2007126865A2 (en) * 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
JP2010511632A (ja) 2006-11-30 2010-04-15 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法
WO2009067317A2 (en) * 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Use of levocabastine for modulating generation of pro- inflammatory cytokines
US20100240624A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic Formulations of Ketotifen and Methods of Use
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
EP3943069A1 (en) 2009-03-17 2022-01-26 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR101418404B1 (ko) 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
CA2906008C (en) 2013-03-13 2019-07-09 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
ES2745041T3 (es) 2013-03-13 2020-02-27 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios
KR101555908B1 (ko) * 2013-12-19 2015-09-25 한미약품 주식회사 몬테루카스트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 액상 제제 및 이의 제조방법
EP3102209B1 (en) 2014-02-04 2021-04-07 Bioscience Pharma Partners, LLC Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US11976052B2 (en) 2019-01-11 2024-05-07 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
CN110721189A (zh) * 2019-11-19 2020-01-24 贵州云峰药业有限公司 一种皮肤消毒剂
NZ790643A (en) 2020-02-03 2023-05-26 Taro Pharma Ind Topical montelukast formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
ATE84968T1 (de) 1987-11-13 1993-02-15 Asta Medica Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
EP0345931B1 (en) * 1988-04-27 1993-01-20 Schering Corporation Certain paf antagonist/antihistamine combinations and methods
ES2284740T3 (es) * 1992-08-03 2007-11-16 Sepracor Inc. Carboxilato de terfenadina y el tratamiento de la irritacion cutanea.
IL125446A0 (en) * 1996-02-08 1999-03-12 Merck & Co Inc Pharmaceutical composition for the treatment of asthma allergy and inflammation
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
AU6878098A (en) * 1997-04-30 1998-11-24 Warner-Lambert Company Topical nasal antiinflammatory compositions
US6242179B1 (en) * 1997-12-17 2001-06-05 Incyte Pharmaceuticals, Inc. Human phosphatases
EP1041990B1 (en) * 1997-12-23 2006-06-28 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors

Also Published As

Publication number Publication date
KR100764329B1 (ko) 2007-10-05
EP1265615A2 (de) 2002-12-18
US6436924B2 (en) 2002-08-20
TWI296525B (en) 2008-05-11
PT1265615E (pt) 2005-05-31
HUP0204079A2 (hu) 2003-04-28
CZ20022700A3 (cs) 2002-11-13
PL355818A1 (en) 2004-05-17
SK11752002A3 (sk) 2002-11-06
WO2001060407A2 (de) 2001-08-23
WO2001060407A3 (de) 2002-03-07
BR0108445A (pt) 2003-04-01
NO20023818D0 (no) 2002-08-12
CZ296395B6 (cs) 2006-03-15
ES2236189T3 (es) 2005-07-16
AU4058401A (en) 2001-08-27
EP1265615B1 (de) 2005-01-19
SK285990B6 (sk) 2008-01-07
HUP0204079A3 (en) 2006-07-28
JP5529362B2 (ja) 2014-06-25
ATE287266T1 (de) 2005-02-15
DE10007203A1 (de) 2001-08-23
AU781177B2 (en) 2005-05-12
DK1265615T3 (da) 2005-05-30
NO328153B1 (no) 2009-12-21
NO20023818L (no) 2002-08-12
IL151106A (en) 2008-06-05
ZA200206575B (en) 2003-05-14
CN1241569C (zh) 2006-02-15
PL198357B1 (pl) 2008-06-30
HK1053792A1 (en) 2003-11-07
UA72587C2 (uk) 2005-03-15
HU228927B1 (en) 2013-06-28
AR027528A1 (es) 2003-04-02
CN1400903A (zh) 2003-03-05
KR20020083161A (ko) 2002-11-01
US20010025040A1 (en) 2001-09-27
RU2002123345A (ru) 2004-03-20
NZ520470A (en) 2004-05-28
MXPA02008064A (es) 2004-04-05
JP2003522803A (ja) 2003-07-29
DE50105126D1 (de) 2005-02-24
RU2292208C2 (ru) 2007-01-27

Similar Documents

Publication Publication Date Title
IL151106A0 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
EP1496878A4 (en) TECHNIQUES FOR IDENTIFYING ANGIOGENESIS MODULATORS, COMPOUNDS DISCOVERED BY THESE TECHNIQUES AND TREATMENT TECHNIQUES USING THESE COMPOUNDS
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
AP2006003558A0 (en) Polymorphic forms of 3-(4-amino-1oxo-1,3 dilhydro-isoindol-2-yl)-piperidine-2,6-dione.
EP1274444A4 (en) DRUGS FOR THE TREATMENT OF PSYCHIATRICAL OR ABUSUS-RELATED DISORDER
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
ZA200204830B (en) Novel method for down-regulation of amyloid.
HK1047425A1 (en) Garbage treatment apparatus.
HK1057363A1 (en) Ccr5 antagonists useful for treating aids.
MXPA03001717A (es) METODO PARA EL TRATAMIENTO DE LA MIGRAnA.
MXPA02012907A (es) Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
IL153559A0 (en) Compounds for treating impaired fundic relaxation
AU2003222022A8 (en) Methods for treating deodorizer distillate
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
MXPA03002517A (es) Proceso de hidrofisuracion.
SI1265615T1 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
HU0002837D0 (en) Strain-setting device for tendonrekonstruction or replacement
IL188685A0 (en) Use of 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer
EP1701470A4 (en) BROADBAND ACCESS DEVICE AND METHOD FOR CONTROLLING DHCP RELAY AGENT
MXPA02000714A (es) Aparato para triturar material.
ITPD20000203A0 (it) Dispositivi di sicurezza per portoni sezionali.
TW479626U (en) Treatment device for junk
TW493386U (en) Stuffing-feeding mechanism without dewatering/deoiling
HK1063981A2 (en) Carton for containing tissue paper.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
FF Patent granted